{"transactions":[{"id":731902,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Unit","published_at":"2026-06-18T21:16:26.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":90316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred restricted stock unit (\"DRSU\") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."}],"balance_after":90316,"derivative":{"underlying":"Common Stock","underlying_shares":90316},"source":{"system":"sec-edgar","filing":"0001104659-26-075858","document":"tm2618145-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926075858/tm2618145-3_4seq1.xml","form_type":"4"}},{"id":750015,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T22:10:15.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":7490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 2, 2026. Price not applicable."}],"balance_after":21040,"source":{"system":"sec-edgar","filing":"0001628280-26-040922","document":"wk-form4_1780611012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026040922/wk-form4_1780611012.xml","form_type":"4"}},{"id":767495,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-21T20:10:38.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":10539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":10539,"derivative":{"exercise_price":5.08,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":10539},"source":{"system":"sec-edgar","filing":"0001571469-26-000002","document":"form4-05212026_080534.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000157146926000002/form4-05212026_080534.xml","form_type":"4"}},{"id":1107836,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Unit","published_at":"2025-06-17T20:09:11.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":67546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred restricted stock unit (\"DRSU\") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."}],"balance_after":67546,"derivative":{"underlying":"Common Stock","underlying_shares":67546},"source":{"system":"sec-edgar","filing":"0001104659-25-060254","document":"tm2518181-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925060254/tm2518181-5_4seq1.xml","form_type":"4"}},{"id":1128915,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-30T23:30:26.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":201857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":201857,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":201857},"source":{"system":"sec-edgar","filing":"0001415889-25-015058","document":"form4-05302025_110515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000141588925015058/form4-05302025_110515.xml","form_type":"4"}},{"id":1137821,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T20:52:41.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":6650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 20, 2025. Price not applicable."}],"balance_after":13550,"source":{"system":"sec-edgar","filing":"0001048477-25-000066","document":"wk-form4_1747947154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000066/wk-form4_1747947154.xml","form_type":"4"}},{"id":1480467,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Unit","published_at":"2024-06-13T22:03:26.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":49303,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred restricted stock unit (\"DRSU\") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."}],"balance_after":49303,"derivative":{"underlying":"Common Stock","underlying_shares":49303},"source":{"system":"sec-edgar","filing":"0001104659-24-071374","document":"tm2417165-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924071374/tm2417165-5_4seq1.xml","form_type":"4"}},{"id":1503268,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-23T21:43:57.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":47693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":47693,"derivative":{"exercise_price":1.28,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":47693},"source":{"system":"sec-edgar","filing":"0001415889-24-014333","document":"form4-05232024_090550.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000141588924014333/form4-05232024_090550.xml","form_type":"4"}},{"id":1504164,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-23T21:14:13.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":4720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 21, 2024. Price not applicable."}],"balance_after":6900,"source":{"system":"sec-edgar","filing":"0001048477-24-000096","document":"wk-form4_1716498842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000096/wk-form4_1716498842.xml","form_type":"4"}},{"id":1595392,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Unit","published_at":"2024-03-05T22:50:53.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred restricted stock unit (\"DRSU\") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-031105","document":"tm248017d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924031105/tm248017d1_4seq1.xml","form_type":"4"}},{"id":1698924,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-28T18:03:59.000Z","date":"2023-12-27","kind":"grant","planned":false,"acquired":true,"shares":2180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on December 27, 2023. Price not applicable."}],"balance_after":2180,"source":{"system":"sec-edgar","filing":"0001048477-23-000068","document":"wk-form4_1703786629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000068/wk-form4_1703786629.xml","form_type":"4"}},{"id":1862117,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Unit","published_at":"2023-06-08T22:22:11.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":51955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred restricted stock unit (\"DRSU\") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."}],"balance_after":51955,"derivative":{"underlying":"Common Stock","underlying_shares":51955},"source":{"system":"sec-edgar","filing":"0001104659-23-069509","document":"tm2318216-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465923069509/tm2318216-6_4seq1.xml","form_type":"4"}},{"id":1876015,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-05-26T20:22:00.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of:  (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":24000,"derivative":{"exercise_price":1,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-23-032542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919123032542/doc4.xml","form_type":"4"}},{"id":2180724,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:23:42.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":224640,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":37.68,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":224640},"source":{"system":"sec-edgar","filing":"0001209191-22-046258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122046258/doc4.xml","form_type":"4"}},{"id":2180723,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:23:42.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":101775,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option."}],"balance_after":0,"derivative":{"exercise_price":140.01,"expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":101775},"source":{"system":"sec-edgar","filing":"0001209191-22-046258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122046258/doc4.xml","form_type":"4"}},{"id":2180722,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:23:42.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":325000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":63.33,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001209191-22-046258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122046258/doc4.xml","form_type":"4"}},{"id":2180721,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:23:42.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":155844,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":7.43,"expiration_date":"2029-02-19","underlying":"Common Stock","underlying_shares":155844},"source":{"system":"sec-edgar","filing":"0001209191-22-046258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122046258/doc4.xml","form_type":"4"}},{"id":2180720,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:23:42.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":989971,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":5.12,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":989971},"source":{"system":"sec-edgar","filing":"0001209191-22-046258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122046258/doc4.xml","form_type":"4"}},{"id":2180719,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:23:42.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":67575,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":3.2,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":67575},"source":{"system":"sec-edgar","filing":"0001209191-22-046258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122046258/doc4.xml","form_type":"4"}},{"id":2180718,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-17T20:23:42.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":173389,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law."}],"balance_after":0,"derivative":{"exercise_price":3.2,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":173389},"source":{"system":"sec-edgar","filing":"0001209191-22-046258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122046258/doc4.xml","form_type":"4"}},{"id":2180717,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-08-17T20:23:42.000Z","date":"2022-08-17","kind":"disposition_to_issuer","acquired":false,"shares":110959,"price":76,"value":8432884.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the \"Issuer\"), Bristol-Myers Squibb Company (\"BMS\") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS (\"Purchaser\"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the \"Cash Amount\"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award (\"RSU\") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 629 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-046258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122046258/doc4.xml","form_type":"4"}},{"id":2232530,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Unit","published_at":"2022-06-14T21:03:44.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":51204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred restricted stock unit (\"DRSU\") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date."}],"balance_after":51204,"derivative":{"underlying":"Common Stock","underlying_shares":51204},"source":{"system":"sec-edgar","filing":"0001104659-22-071056","document":"tm2218366-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465922071056/tm2218366-7_4seq1.xml","form_type":"4"}},{"id":2250886,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-05-31T20:20:34.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of:  (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":24000,"derivative":{"exercise_price":1.76,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-22-032807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122032807/doc4.xml","form_type":"4"}},{"id":2401067,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-11T23:07:55.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":224640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares vest monthly following February 9, 2022."}],"balance_after":224640,"derivative":{"exercise_price":37.68,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":224640},"source":{"system":"sec-edgar","filing":"0001209191-22-008979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122008979/doc4.xml","form_type":"4"}},{"id":2401066,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-11T23:07:55.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":62400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan."}],"balance_after":110330,"source":{"system":"sec-edgar","filing":"0001209191-22-008979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122008979/doc4.xml","form_type":"4"}},{"id":2401065,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-11T23:07:55.000Z","date":"2022-02-09","kind":"sale","acquired":false,"shares":2971,"price":36.3,"value":107847.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person acquired 706 shares on June 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan (the \"ESPP\")."}],"balance_after":47930,"source":{"system":"sec-edgar","filing":"0001209191-22-008979","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919122008979/doc4.xml","form_type":"4"}},{"id":2647481,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T20:17:16.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 29, 2022."}],"balance_after":35000,"derivative":{"exercise_price":26.33,"expiration_date":"2031-06-29","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-21-088245","document":"tm2121236-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465921088245/tm2121236-1_4seq1.xml","form_type":"4"}},{"id":2690783,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-28T21:50:39.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":16918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16918,"derivative":{"exercise_price":13.83,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":16918},"source":{"system":"sec-edgar","filing":"0001209191-21-036616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121036616/doc4.xml","form_type":"4"}},{"id":2865782,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-11","kind":"exercise","acquired":false,"shares":8942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"25% of the shares vested on May 7, 2019 and 1/48th of the shares vest monthly thereafter over the next three years."}],"balance_after":173389,"derivative":{"exercise_price":3.2,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":8942},"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865781,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-10","kind":"exercise","acquired":false,"shares":25392,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"25% of the shares vested on May 7, 2019 and 1/48th of the shares vest monthly thereafter over the next three years."}],"balance_after":182331,"derivative":{"exercise_price":3.2,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":25392},"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865780,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":7666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"25% of the shares vested on June 29, 2019 and 1/48th of the shares vest monthly thereafter over the next three years."}],"balance_after":67575,"derivative":{"exercise_price":3.2,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":7666},"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865779,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"25% of the shares vested on May 7, 2019 and 1/48th of the shares vest monthly thereafter over the next three years."}],"balance_after":207723,"derivative":{"exercise_price":3.2,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865778,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":3052,"price":138.55,"value":422854.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The weighted average sale price for the transaction reported was $138.55, and the range of prices were between $138.09 and $139.00.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":50195,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865777,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":1571,"price":137.66,"value":216263.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The weighted average sale price for the transaction reported was $137.66, and the range of prices were between $137.025 and $138.00.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":53247,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865776,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":4319,"price":136.45,"value":589327.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The weighted average sale price for the transaction reported was $136.45, and the range of prices were between $136.00 and $137.00.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":54818,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865775,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-11","kind":"exercise","acquired":true,"shares":8942,"price":3.2,"value":28614.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":59137,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865774,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":433,"price":138.19,"value":59836.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The weighted average sale price for the transaction reported was $138.19, and the range of prices were between $138.05 and $138.425.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":50195,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865773,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":2081,"price":137.46,"value":286054.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The weighted average sale price for the transaction reported was $137.46, and the range of prices were between $137.04 and $138.04.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":50628,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865772,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":16626,"price":136.42,"value":2268118.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The weighted average sale price for the transaction reported was $136.42, and the range of prices were between $136.02 and $137.02.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":52709,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865771,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":5227,"price":135.72,"value":709408.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The weighted average sale price for the transaction reported was $135.72, and the range of prices were between $135.015 and $136.015.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":69335,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865770,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":1025,"price":134.34,"value":137698.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The weighted average sale price for the transaction reported was $134.34, and the range of prices were between $134.00 and $135.00.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":74562,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865769,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-10","kind":"exercise","acquired":true,"shares":25392,"price":3.2,"value":81254.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":75587,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865768,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":1104,"price":140.24,"value":154824.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The weighted average sale price for the transaction reported was $140.24, and the range of prices were between $140.24 and $140.39.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":50195,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865767,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":13290,"price":139.69,"value":1856480.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The weighted average sale price for the transaction reported was $139.69, and the range of prices were between $139.235 and $140.10.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":51299,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865766,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":4969,"price":138.66,"value":689001.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $138.66, and the range of prices were between $138.09 and $139.085.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":64589,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865765,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":103,"price":137.58,"value":14170.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $137.58, and the range of prices were between $137.035 and $138.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":69558,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865764,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":6200,"price":136.29,"value":844998.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $136.29, and the range of prices were between $136.00 and $137.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":69661,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865763,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":7666,"price":3.2,"value":24531.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":75861,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2865762,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-12T01:28:35.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":18000,"price":3.2,"value":57600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020."}],"balance_after":68195,"source":{"system":"sec-edgar","filing":"0001209191-21-009931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009931/doc4.xml","form_type":"4"}},{"id":2868567,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right  to buy)","published_at":"2021-02-10T22:52:23.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":101775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares vest monthly following February 8, 2021."}],"balance_after":101775,"derivative":{"exercise_price":140.01,"expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":101775},"source":{"system":"sec-edgar","filing":"0001209191-21-009357","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009357/doc4.xml","form_type":"4"}},{"id":2868566,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-10T22:52:23.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":22617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 369 shares acquired by the Reporting Person on June 10, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the \"ESPP\") and 337 shares acquired on December 10, 2020 pursuant the ESPP."}],"balance_after":50195,"source":{"system":"sec-edgar","filing":"0001209191-21-009357","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919121009357/doc4.xml","form_type":"4"}},{"id":3114620,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T00:00:20.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 8, 2021."}],"balance_after":35000,"derivative":{"exercise_price":32.17,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-20-072137","document":"tm2022303d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465920072137/tm2022303d1_4.xml","form_type":"4"}},{"id":3134717,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-05-26T21:55:17.000Z","date":"2020-05-21","kind":"purchase","acquired":true,"shares":4166,"price":60,"value":249960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were purchased in connection with the Issuer's public offering."}],"balance_after":26872,"source":{"system":"sec-edgar","filing":"0001209191-20-032143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919120032143/doc4.xml","form_type":"4"}},{"id":3195012,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-26T00:26:08.000Z","date":"2020-03-24","kind":"purchase","acquired":true,"shares":10000,"price":14.975,"value":149750.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $14.79 to $15.00 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":18900,"source":{"system":"sec-edgar","filing":"0001209191-20-021188","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919120021188/doc4.xml","form_type":"4"}},{"id":3230827,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T23:37:25.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":8900,"price":18,"value":160200.0,"ownership":{"direct":true},"balance_after":8900,"source":{"system":"sec-edgar","filing":"0001209191-20-015619","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919120015619/doc4.xml","form_type":"4"}},{"id":3237312,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-03-02T23:05:36.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":33836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":33836,"derivative":{"exercise_price":18,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":33836},"source":{"system":"sec-edgar","filing":"0001209191-20-014706","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919120014706/doc4.xml","form_type":"4"}},{"id":3314999,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-08T21:24:51.000Z","date":"2020-01-06","kind":"grant","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares will vest each month following January 6, 2020, so that all of the shares are vested four (4) years after January 6, 2020."}],"balance_after":325000,"derivative":{"exercise_price":63.33,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001209191-20-002517","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919120002517/doc4.xml","form_type":"4"}},{"id":3314998,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-01-08T21:24:51.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":706,"price":31.127,"value":21975.662,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person acquired 706 shares on December 10, 2019 at $31.127 per share pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":22706,"source":{"system":"sec-edgar","filing":"0001209191-20-002517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919120002517/doc4.xml","form_type":"4"}},{"id":3417182,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-09-11T20:15:00.000Z","date":"2019-09-10","kind":"purchase","acquired":true,"shares":10000,"price":45,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were purchased in connection with the Issuer's public offering."}],"balance_after":22000,"source":{"system":"sec-edgar","filing":"0001209191-19-049146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919119049146/doc4.xml","form_type":"4"}},{"id":3479880,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-06-24T20:05:39.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":44734,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":46019,"derivative":{"exercise_price":2.48,"exercise_date":"2020-06-20","expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":44734},"source":{"system":"sec-edgar","filing":"0000899243-19-017916","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000089924319017916/doc4.xml","form_type":"4"}},{"id":3494034,"issuer":{"id":2090,"kind":"organization","name":"IOVANCE BIOTHERAPEUTICS, INC.","symbol":"IOVA"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T21:16:15.000Z","date":"2019-06-10","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service, unless the Reporting Person is terminated for cause, in which case the options shall terminate immediately."}],"balance_after":35000,"derivative":{"exercise_price":19.93,"expiration_date":"2029-06-09","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001144204-19-030593","document":"tv523378_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425205/000114420419030593/tv523378_4.xml","form_type":"4"}},{"id":3549894,"issuer":{"id":124461,"kind":"organization","name":"Turning Point Therapeutics, Inc.","symbol":"TPTX"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-04-24T21:55:48.000Z","date":"2019-04-22","kind":"purchase","acquired":true,"shares":12000,"price":18,"value":216000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were purchased at the Issuer's initial public offering."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001209191-19-025786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571469/000120919119025786/doc4.xml","form_type":"4"}},{"id":4046895,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-20T19:16:22.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 15, 2018 (the \"Vesting Commencement Date\"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":160000,"derivative":{"exercise_price":6.4,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-18-011601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919118011601/doc4.xml","form_type":"4"}},{"id":4089566,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2018-01-25T22:00:36.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":54322,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":92428,"derivative":{"exercise_price":0.3,"exercise_date":"2019-01-23","expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":54322},"source":{"system":"sec-edgar","filing":"0000899243-18-001901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000089924318001901/doc4.xml","form_type":"4"}},{"id":4275118,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-21T18:11:58.000Z","date":"2017-06-19","kind":"grant","acquired":true,"shares":213000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the total shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48 of the total shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall be vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":213000,"derivative":{"exercise_price":2.9,"expiration_date":"2027-06-18","underlying":"Common Stock","underlying_shares":213000},"source":{"system":"sec-edgar","filing":"0001209191-17-041253","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919117041253/doc4.xml","form_type":"4"}},{"id":4275117,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-06-21T18:11:58.000Z","date":"2017-06-19","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) RSU upon the vesting thereof. Such RSUs vest with respect to twenty-five percent (25%) of the shares subject thereto on each anniversary of June 19, 2017 (the \"Vesting Commencement Date\"), such that all of the shares subject to the RSUs shall be vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001209191-17-041253","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501756/000120919117041253/doc4.xml","form_type":"4"}},{"id":4424937,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-24T21:06:20.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":45568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter."}],"balance_after":45568,"derivative":{"exercise_price":0,"exercise_date":"2018-02-22","underlying":"Common Stock","underlying_shares":45568},"source":{"system":"sec-edgar","filing":"0001179110-17-003119","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017003119/edgar.xml","form_type":"4"}},{"id":4424936,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2017-02-24T21:06:20.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":72925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":72925,"derivative":{"exercise_price":12.07,"exercise_date":"2018-02-22","expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":72925},"source":{"system":"sec-edgar","filing":"0001179110-17-003119","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017003119/edgar.xml","form_type":"4"}},{"id":4466571,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-07T00:01:29.000Z","date":"2017-02-03","kind":"exercise","acquired":false,"shares":18496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":55487,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":18496},"source":{"system":"sec-edgar","filing":"0001179110-17-001809","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017001809/edgar.xml","form_type":"4"}},{"id":4466570,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-02-07T00:01:29.000Z","date":"2017-02-03","kind":"tax_withholding","acquired":false,"shares":6900,"price":12.26,"value":84594.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 6,900 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations."}],"balance_after":39077,"source":{"system":"sec-edgar","filing":"0001179110-17-001809","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017001809/edgar.xml","form_type":"4"}},{"id":4466569,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-02-07T00:01:29.000Z","date":"2017-02-03","kind":"exercise","acquired":true,"shares":18496,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":45977,"source":{"system":"sec-edgar","filing":"0001179110-17-001809","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017001809/edgar.xml","form_type":"4"}},{"id":4495253,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2017-01-09T21:03:53.000Z","date":"2017-01-05","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-17-000756","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017000756/edgar.xml","form_type":"4"}},{"id":4495252,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36776,"kind":"person","name":"Countouriotis Athena","position":1,"cik":"0001571469","reported_name":"Countouriotis Athena","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-09T21:03:53.000Z","date":"2017-01-05","kind":"exercise","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27481,"source":{"system":"sec-edgar","filing":"0001179110-17-000756","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017000756/edgar.xml","form_type":"4"}}]}